Orchard Therapeutics said on July 15th that it has licensed lentiviral stable cell line technology from GlaxoSmithKline for use in its hematopoietic stem cell gene therapies. GSK filed for patents on the technology before selling its rare disease gene therapy portfolio to Orchard in 2018. The use of lentiviral vectors to modify hematopoietic stem cells outside of the body has resulted in gene therapies that have shown promise in people with multiple disorders, including complex genetic diseases. However, the complexity of clinical-grade lentiviral vector production has presented a barrier to the approach and driven up the time and money needed to make the therapies. Last year, researchers at GSK and Orchard shared a look at a way to address that barrier. The idea is to introduce all the required lentiviral vector components into the cell at once rather than execute a sequential series of gene transfer steps. Orchard sees big advantages to the approach.
For further information, see FierceBiotech (https://www.fiercebiotech.com/biotech/orchard-licenses-gene-therapy-tech-from-gsk)